The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testing
Authors:
Open Access
- 24 October 2025
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-16
Abstract
Genetic testing has become more complex with the transition from single gene testing to multi-gene panels and whole-exome sequencing. The adoption of more complex genetic testing and the promise of precision medicine has created a critical and urgent need for longitudinal clinical follow-up with patients who undergo cancer genetic testing given the residual uncertainty. There is an increasing need for multidisciplinary translational research that focuses on how to advance precision medicine discoveries into clinical practice and to capitalize on connectivity (e.g. digital health) interventions in ways that optimize cancer risk reducing behaviors in real-world clinical populations. The overall goal of this Hybrid Type 1 effectiveness-implementation randomized study is to evaluate the effectiveness of the MyCancerGene intervention to improve longitudinal (short-term and long-term) understanding (e.g. knowledge) and reactions to (e.g. anxiety) clinical genetic testing compared to usual care. We hypothesize that access to MyCancerGene will be associated with short-term and post-disclosure increases in knowledge, decreases in distress, increases in communication with relatives and health care providers and performance of risk reducing health behaviors compared to usual care. Equally important, we hypothesize that our implementation process evaluation will inform recommendations for future adaptation and sustainability for other precision medicine applications. Given the increasing complexity of genetic testing applications (e.g. multi-gene testing, whole exome sequencing) and the need for post-disclosure follow-up, we expect this study to inform evidence-based practice guidelines for delivery of genetic medicine and potentially change the paradigm to include longitudinal care in precision medicine. To address the clinically significant gap in the delivery of genetic medicine, patient and provider stakeholder input have been used to develop a patient and provider informed centered genetic digital health portal to enhance patient understanding of, and affective and behavioral responses to genetic testing, particularly in the era of evolving evidence and risk information. This protocol was registered at clinicaltrials.gov (NCT04774445) in February 18, 2021.Keywords
Funding Information
- American Cancer Society (RSG-18-192-CPHPS)
This publication has 100 references indexed in Scilit:
- Information needs persist after genetic counseling and testing for BRCA1/2 and Lynch SyndromeBreast Cancer Research and Treatment, 2024
- Psychological distress following multi‐gene panel testing for hereditary breast and ovarian cancer riskJournal of Genetic Counseling, 2024
- Perspectives of Patients About Immediate Access to Test Results Through an Online Patient PortalJAMA Network Open, 2023
- Impact of COVID‐19 pandemic on a large cohort of adult survivors of childhood cancerPediatric Blood & Cancer, 2021
- Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patientsCancer, 2020
- Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer careCancer, 2014
- Delivery of Genomic Medicine for Common Chronic Adult DiseasesJAMA, 2008
- Interactive Health Communication Applications for people with chronic diseaseCochrane Database of Systematic Reviews, 2005
- Using the common sense model to understand perceived cancer risk in individuals testing for BRCA1/2 mutationsPsycho-Oncology, 2004
- Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testingAmerican Journal of Medical Genetics Part A, 2003